IL13 and atopic eczema: Dupilumab, another drug directed on T2 inflammation mechanisms, was precisely directed to the IL-4 receptor, which is a molecule that can interact both with IL-4 and IL-13 (currently used in atopic dermatitis, nasal polyposis, and asthma).